Status:
COMPLETED
Ibrutinib for Relapsed or Refractory Mantle Cell Lymphoma
Lead Sponsor:
Samsung Medical Center
Conditions:
Mantle Cell Lymphoma
Eligibility:
All Genders
19+ years
Brief Summary
To review the efficacy and the safety of ibrutinib in patients with relapsed or refractory mantle cell lymphoma (MCL).
Detailed Description
\# Background and Rationale Mantle cell lymphoma (MCL) is a rare subtype of lymphoma, accounting for about 3-6% of all non-Hodgkin's lymphoma. It is clinically prevalent in the elderly and men, common...
Eligibility Criteria
Inclusion
- Patients with MCL diagnosed by a pathologist (based on the WHO 2017 classification)
- mantle cell lymphoma
- leukemic nonnodal mantle cell lymphoma
- in situ mantle cell neoplasia
- Aged ≥ 19 years
- Relapsed or refractory patients treated with ibrutinib, including relapse after autologous stem cell transplantation
Exclusion
- Patients whose clinical and pathological data are not available
- Patients who were not treated with ibrutinib
Key Trial Info
Start Date :
July 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 31 2020
Estimated Enrollment :
88 Patients enrolled
Trial Details
Trial ID
NCT04061850
Start Date
July 1 2019
End Date
August 31 2020
Last Update
October 22 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
81, Irwon-ro, Gangnam-gu, Seoul, Republic of Korea
Seoul, South Korea, 06351